OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Rheumatology is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
No benefit from adding MTX to ustekinumab	525
Bimekizumab effective across the axSpA spectrum	455
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	342
Genome-wide mutagenesis reported in systemic sclerosis	302
The role of the patient in rheumatology	277
Reply to ‘Potential benefit of anticoagulation in Behçet syndrome’	232
A role for TGFβ and EBV in MIS-C pathogenesis	218
Rheumatic diseases on the rise	199
Osteoarthritis as a systemic disease	181
Biological and clinical roles of IL-18 in inflammatory diseases	180
Towards better management of sterile bone inflammation	168
New drug formulation reduces bone loss	162
The value of comparative efficacy studies in informing rheumatology guidelines	160
To choose or not? The value of discrete-choice experiments in rheumatology	160
The 2022 ACR vaccination guideline: a call-to-action	157
MIS-C: myths have been debunked, but mysteries remain	150
Appraising the evolving landscape of protease inhibition in osteoarthritis	150
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?	146
FOXP3 splice variant is associated with autoimmune disease	137
Down syndrome: insights into autoimmune mechanisms	135
Urchin-like nanoparticles for miRNA therapy of OA	131
Inflammation across tissues: can shared cell biology help design smarter trials?	131
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	126
Addressing the challenge of global delays in diagnosis and treatment of systemic lupus erythematosus	122
Low-dose glucocorticoids benefit seniors with RA	120

Co-trimoxazole reduces mortality in anti-MDA5-DM	119
Immune reset and immune retune: approaching cure?	114
Fibroblast TGFβ drives treatment-refractory RA	113
Wnt-induced IGF1 drives OA	108
A direct link between SARS-CoV-2 and bone loss	108
COPA syndrome spans multiple organs but is defined by STING in the lung	108
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?	108
Author Correction: Proposals for the rheumatological use of JAK inhibitors	104
Calprotectin tracks tocilizumab-treated RA	100
Fumarate drives interferon release in systemic sclerosis monocytes	99
Pain in systemic lupus erythematosus: emerging insights and paradigms	95
S100A4 inhibition targets fibrosis in SSc	95
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	91
Low back pain is a growing concern	90
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis	87
Rheumatic diseases and metabolism: where centre and periphery meet	85
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	80
Rheumatology in the digital health era: status quo and quo vadis?	79
Guiding ILD management in systemic autoimmune rheumatic diseases	79
Targeting the IVD clock to halt degeneration	76
Which DMARD for ICI-associated arthritis?	75
Phase III trial of telitacicept in SLE	71
A path towards personalized medicine for autoinflammatory and related diseases	68
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus	66
Cell-free DNA fragmentation signatures link cancer and autoimmunity	66
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	66
Erosive cargo from synovial fibroblasts	65
Insights into IVDD pathogenesis in 2024	62
ERAP1 and the return of the UPR in ankylosing spondylitis	60
Macrophage-coated nanocarriers for gouty arthritis	59
CAR T cells induce drug-free SLE remission	59
RA risk from occupational inhalation	58
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	58
Blocking CDK7 attenuates inflammatory arthritis	56
Fibroblast heterogeneity in 2025	55
Repolarizing macrophages using antagomirs	55
A critical view of WHO guidelines on management of low back pain	53
All fibroblasts are equal, but some are more equal than others	52
New refinements aim to optimize articular cartilage tissue engineering	50
New developments in electronic health record analysis	49
TASL has a key role in SLE	49
Two sides of management recommendations for psoriatic arthritis	49
A leading role for interferon as a treatment target in Sjögren syndrome	47
Platelets as drivers of immunothrombosis in rheumatic diseases	47
Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis	47
Profiling joint tissues at single-cell resolution: advances and insights	46
Innate lymphoid cells in rheumatoid arthritis as mediators of pathology and resolution	45
Unravelling the cellular mechanisms of VEXAS syndrome	43
Reply to ‘Is cam morphology a cause of osteoarthritis?’	43
AhR promotes suppressor cell function in Sjögren syndrome	43

Clarity for the language of race, ethnicity and genetic ancestry in rheumatology	43
Author Correction: Glycobiology of rheumatic diseases	42
Piezo1 induces new bone formation in AS	42
Author Correction: International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	40
Treg cell-inducing nanoparticles show promise for treating OA	39
Pathogenic antibodies target stromal antigens in RA	38
CXCL5 effective in mouse model of SLE	36
Metabolic masqueraders of paediatric and adult rheumatic diseases	36
Fertility, pregnancy and lactation in women with systemic lupus erythematosus	34
l-arginine inhibits arthritis and bone loss by reprogramming osteoclast metabolism	34
Publisher Correction: The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET	34
APOE in fat pad and synovium contributes to knee OA	34
Sex- and gender-based personalized medicine in rheumatology	33
IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting	33
Rethinking early-stage knee osteoarthritis beyond radiography	33
The obesity–inflammation axis in psoriatic disease: mechanisms and therapeutic strategies	33
Shifting the SLE management paradigm: challenges and implications	32
PDGFR signalling implicated in anti-resorptive effects of sclerostin blockade	31
STING-driven necroptosis linked to autoinflammatory disease	30
Senotherapeutics suppress disc degeneration	30
In vivo CAR-T cell engineering in refractory SLE	29
Post-transcriptional checkpoints in autoimmunity	29
Location-specific treatment of chronic inflammatory joint disease	29
BiTE therapy for rheumatic diseases	29
Parathyroid hormone receptor agonists in the management of osteoporosis	28
Critical appraisal of serum urate targets in the management of gout	27
Interferon disrupts immune and tissue homeostasis in SLE via CXCL13	27
FABP4 exacerbates RA	26
Multi-omics reveals distinct MPA subtypes	26
Detachment promotes RA synovial fibroblast survival and invasiveness	26
COVID-19 linked to rise in anti-MDA5 autoimmunity	25
Adropin inhibits fibrosis in SSc	25
State-of-the-art evidence in the treatment of systemic sclerosis	24
Engineered sialylated IgG1 Fc as a dose-sparing alternative to IVIG	24
Complement therapeutics are coming of age in rheumatology	24
Notch signalling mediates OA pain in mice	24
Busting the myth of methotrexate chronic hepatotoxicity	24
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis	23
The potential contribution of in silico studies to improved treatment of osteoarthritis	23
Citrulline immunity in RA: CD8+ T cells enter the scene	23
Synovial fluid as a complex molecular pool contributing to knee osteoarthritis	22
Single-cell RNA sequencing sheds light on cell-type specific gene expression in immune cells	22
Identifying fibromyalgia phenotypes based on psychological symptom burden	20
Treatment of non-systemic juvenile idiopathic arthritis	20
What rheumatology can learn from oncology: a patient’s perspective	20
Update on the pathophysiology and treatment of primary Sjögren syndrome	19
Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions	19
Undiagnosed axSpA is prevalent in IBD	18
The immune health metric as an indicator of health and disease	18
Glycosylation switch in synovial fibroblasts promotes ECM degradation	18
The PU.1– IL-9 axis in TH9 cells promotes RA	18
Primary care rheumatology: towards sustainable development in health	17
Bone-modifying drugs slow OA progression	17
UNC93B1 variants promote SLE via TLR activation	17
Low-frequency and rare genetic variants associated with rheumatoid arthritis risk	17
Combination therapy for Behçet uveitis	17
Shedding light onto the immunometabolic effects of glucocorticoids	16
Advances in understanding preclinical rheumatoid arthritis and prospects for prevention	16
SIX1 and PAI-1 emerge as therapeutic targets in systemic sclerosis	16
Lupus ABC spearheading a new era of collaboration to advance lupus drug development	16
Advances in viscosupplementation and tribosupplementation for early-stage osteoarthritis therapy	15
The role of the immune system in osteoarthritis: mechanisms, challenges and future directions	15
More than a leaky gut: how gut priming shapes arthritis	14
Reversal of inflammatory priming prevents arthritic flares	14
Rheumatoid arthritis prevention in arthralgia: fantasy or reality?	14
Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?	13
Paediatric glucocorticoid toxicity index: new possibilities in assessment	13
T cell differentiation in Sjögren syndrome is regulated by TOX	13
Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy	12
Disease stratification in GCA and PMR: state of the art and future perspectives	12
New guide calls for interdisciplinary approach to TMJ arthritis symptoms	12
Current challenges in understanding the epidemiology of calcium pyrophosphate crystal deposition	12
Advances in the calculation of minimal important change estimates for patient-reported outcome measures	12
The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies	12
Global epidemiology of spondyloarthritis	12
Neurodevelopmental comorbidities in juvenile systemic autoimmune and autoinflammatory diseases	12
Evidence-Based Guideline for the management of osteoporosis in men	12